SCHEMBL6738807

SCHEMBL6738807

O=c1c(C2=NS(=O)(=O)c3cc(O)ccc3N2)c(O)c2cc(O)ccc2n1CCC1CC1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.72
NR1I2 O75469 1/20 0.72
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
WEE1 P30291 9/20 0.34
PLK1 P53350 1/20 0.32
PARG Q86W56 1/20 0.32
CHEK1 O14757 3/20 0.31
HIF1A Q16665 1/20 0.31
SRC P12931 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6690316 0.94 CYP2C9 (0.83) CYP2C9NR1I2MAPK1HSD17B10CA12
SCHEMBL6693292 0.93 CYP2C9 (0.70) CYP2C9NR1I2MAPK1HSD17B10CA12
SCHEMBL6693468 0.86 CYP2C9 (0.81) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6232054 0.85 CYP2C9 (0.80) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6732547 0.85 CYP2C9 (0.69) CYP2C9NR1I2MAPK1HSD17B10HIF1A
SCHEMBL6732912 0.84 MAPK1 (0.57) CYP2C9NR1I2MAPK1HSD17B10CA12
SCHEMBL6688684 0.84 CYP2C9 (0.78) CYP2C9NR1I2MAPK1HSD17B10PLK1
SCHEMBL6689772 0.84 CYP2C9 (0.78) CYP2C9NR1I2MAPK1HSD17B10CA12
SCHEMBL6738190 0.84 CYP2C9 (0.81) CYP2C9NR1I2MAPK1HSD17B10CA12
SCHEMBL5089690 0.84 CYP2C9 (1.00) CYP2C9NR1I2MAPK1HSD17B10PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 CYP2C9 1218/4885NR1I2 1798/4885MAPK1 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.